Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A 1-year Randomised, Double-blind Placebo-controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients With Alzheimer's Disease
Authors not listed
H. Lundbeck A/S · 2005
Abstract
Pre-clinical studies have demonstrated that memantine can decrease the neuronal toxicity associated with excessive glutamate release and calcium overload in neurons. Previous studies have shown that memantine helps to treat the symptoms of Alzheimer's Disease (AD). In AD, the rate of brain tissue loss, or atrophy, is faster than in normal aging and this seems to go hand in hand with some of the symptoms of the disease. This suggests that memantine treatment in AD could provide both symptomatic improvement and neuro-protective effects. The purpose of this study was to show whether memantine, in addition to providing symptomatic benefits, can slow the rate of brain atrophy as assessed using magnetic resonance imaging (MRI) technology.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
Anonymous. (2005). A 1-year Randomised, Double-blind Placebo-controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients With Alzheimer's Disease. <em>H. Lundbeck A/S</em>. https://clinicaltrials.gov/study/NCT00862940
Vancouver
Anonymous. A 1-year Randomised, Double-blind Placebo-controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients With Alzheimer's Disease. H. Lundbeck A/S. 2005.
BibTeX
@misc{anon2005AyearR,
title = {A 1-year Randomised, Double-blind Placebo-controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients With Alzheimer's Disease},
author = {Anonymous},
journal = {H. Lundbeck A/S},
year = {2005},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
2014
Citation only
Effects of genetic variation on the dynamics of neurodegeneration in Alzheimer's disease
Acta Neuropathologica 2003
Citation only
α-Synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution—a pilot study
PLoS ONE 2013
Open access · CC-BY
Characterizing the Role of Brain Derived Neurotrophic Factor Genetic Variation in Alzheimer’s Disease Neurodegeneration
US Department of Veterans Affairs 1998
Open access · US-GOV
Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen
Journal of Alzheimer's disease : JAD 2026
Citation only
Changes in gray matter volume associated with gait speed and muscle mass in older adults with mild cognitive impairment.
British Journal of Pharmacology 2007
Open access · OA